CMPS · Insider Trading
COMPASS Pathways Plc American Depository Shares
Every open-market purchase and sale reported by CMPS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Kabir Nath | Chief Executive Officer | F | −5,962 | −$67.07K |
| 2026-05-29 | Gino Santini | Director | A | +30,158 deriv. | — |
| 2026-05-29 | Robert McQuade | Director | A | +21,110 deriv. | — |
| 2026-05-29 | David Y Norton | Director | A | +21,110 deriv. | — |
| 2026-05-29 | Wayne Joseph Riley | Director | A | +21,110 deriv. | — |
| 2026-05-29 | Daphne Karydas | Director | A | +21,110 deriv. | — |
| 2026-05-29 | Justin D. Gover | Director | A | +21,110 deriv. | — |
| 2026-05-29 | Jeffrey M Jonas | Director | A | +21,110 deriv. | — |
| 2026-05-29 | Kathleen Tregoning | Director | A | +41,119 deriv. | — |
| 2026-03-27 | Kabir Nath | Chief Executive Officer | A | +175,000 | — |
| 2026-03-27 | Guy Goodwin | Chief Medical Officer | A | +170,600 deriv. | — |
| 2026-03-27 | Teri Loxam | Chief Financial Officer | A | +75,000 | — |
| 2026-03-13 | Teri Loxam | Chief Financial Officer | F | −1,781 | −$12.27K |
| 2026-03-13 | Kabir Nath | Chief Executive Officer | F | −13,131 | −$90.47K |
| 2026-03-03 | Teri Loxam | Chief Financial Officer | F | −4,467 | −$31.36K |
| 2026-02-03 | Kabir Nath | Chief Executive Officer | F | −16,181 | −$106.96K |
| 2025-10-31 | Jeffrey M Jonas | Director | A | +52,000 deriv. | — |
| 2025-08-04 | Kabir Nath | Chief Executive Officer | F | −6,366 | −$27.63K |
| 2025-07-30 | Justin D. Gover | Director | A | +52,000 deriv. | — |
| 2025-06-13 | Annalisa Jenkins | Director | A | +26,000 deriv. | — |
| 2025-06-13 | Gino Santini | Director | A | +39,000 deriv. | — |
| 2025-06-13 | Thomas Lonngren | Director | A | +26,000 deriv. | — |
| 2025-06-13 | Daphne Karydas | Director | A | +26,000 deriv. | — |
| 2025-06-13 | Wayne Joseph Riley | Director | A | +26,000 deriv. | — |
| 2025-06-13 | Robert McQuade | Director | A | +26,000 deriv. | — |
| 2025-06-13 | David Y Norton | Director | A | +26,000 deriv. | — |
| 2025-06-13 | Linda McGoldrick | Director | A | +26,000 deriv. | — |
| 2025-03-13 | Guy Goodwin | Chief Medical Officer | A | +95,000 deriv. | — |
| 2025-03-13 | Kabir Nath | Chief Executive Officer | A | +92,000 | — |
| 2025-03-13 | Teri Loxam | Chief Financial Officer | A | +25,000 | — |
| 2025-03-04 | Teri Loxam | Chief Financial Officer | F | −4,468 | −$16.40K |
| 2025-02-05 | Kabir Nath | Chief Executive Officer | F | −15,516 | −$66.87K |
| 2024-10-25 | George Jay Goldsmith | 10%+ Owner | Sell | −1,553,130 | — |
| 2024-10-25 | Ekaterina Malievskaia | 10%+ Owner | Sell | −1,553,130 | — |
| 2024-09-27 | ATAI Life Sciences AG | 10%+ Owner | Sell | −5,320,000 | −$32.19M |
| 2024-09-04 | Gino Santini | Director | A | +52,000 deriv. | — |
| 2024-08-05 | Kabir Nath | Chief Executive Officer | F | −7,064 | −$48.60K |
| 2024-08-05 | Annalisa Jenkins | Director | F | −161 | −$1.11K |
| 2024-05-22 | Ekaterina Malievskaia | 10%+ Owner | Sell | −31,207 | −$246.57K |
| 2024-05-22 | George Jay Goldsmith | 10%+ Owner | Sell | −31,207 | −$246.57K |
| 2024-05-13 | Wayne Joseph Riley | Director | A | +26,000 deriv. | — |
| 2024-05-13 | Thomas Lonngren | Director | A | +26,000 deriv. | — |
| 2024-05-13 | Annalisa Jenkins | Director | A | +26,000 deriv. | — |
| 2024-05-13 | Daphne Karydas | Director | A | +26,000 deriv. | — |
| 2024-05-13 | Robert McQuade | Director | A | +26,000 deriv. | — |
| 2024-05-13 | David Y Norton | Director | A | +39,000 deriv. | — |
| 2024-05-13 | Linda McGoldrick | Director | A | +26,000 deriv. | — |
| 2024-05-06 | George Jay Goldsmith | 10%+ Owner | Sell | −56,766 | −$490.43K |
| 2024-05-06 | Ekaterina Malievskaia | 10%+ Owner | Sell | −56,766 | −$490.43K |
| 2024-05-03 | Annalisa Jenkins | Director | F | −211 | −$1.79K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kabir Nath | Chief Executive Officer | 361,028 | $3.99M |
| Teri Loxam | Chief Financial Officer | 152,002 | $1.68M |
| David Y Norton | Director | 20,356 | $224.93K |
| Annalisa Jenkins | Director | 19,480 | $215.25K |
| Guy Goodwin | Chief Medical Officer | 8,000 | $88.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMPS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.